Exclusive: NHS to use AI to identify people at higher risk of hepatitis C
Screening programme will detect people with the deadly infection, which is often symptomless in early stagesThe NHS is to use artificial intelligence to detect, screen and treat people at risk of hepatitis C under plans to eradicate the disease by 2030.Hepatitis C often does not have any noticeable symptoms until the liver has been severely damaged, which means thousands of people are living with the infection – known as the silent killer – without realising it.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - July 31, 2022 Category: Science Authors: Andrew Gregory Health editor Tags: Hepatitis C UK news NHS Health Medical research Source Type: news

Enhanced surveillance of childhood cases of hepatitis B and C in England
This protocol details the objectives and methods of collection for the surveillance of childhood cases of hepatitis B and hepatitis C in England. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 28, 2022 Category: Consumer Health News Source Type: news

Rwanda: World Hepatitis Day - How Rwanda Reached Last Mile in Eliminating the Virus
[New Times] As part of the national plan to eliminate Viral Hepatitis C (HCV), Rwanda has so far screened 7 million people, including children and adults, and treated close to 60,000 people, according to Rwanda Biomedical Centre (RBC). (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 28, 2022 Category: African Health Source Type: news

The & quot;Netflix Model & quot; for Hepatitis C Virus Therapies The & quot;Netflix Model & quot; for Hepatitis C Virus Therapies
This paper describes the development and implementation of a novel subscription-based pricing model for HCV therapeutics, the Payer License Agreement.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 26, 2022 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Childhood hepatitis surge ‘probably linked to two common viruses’
Scientists say simultaneous infection with viruses may explain rise in cases, with 12 UK children requiring liver transplantsSimultaneous infection with two common viruses is thought to explain a recent surge inchildhood hepatitis cases, which has led to 12 UK children requiring liver transplants so far.Two research groups have detected high levels of adeno-associated virus 2 (AAV2) – a little-known virus not previously associated with human disease – in almost all of the affected British children they have tested. AAV2 is unable to replicate by itself but can do so in the presence of a second virus.Continue reading......
Source: Guardian Unlimited Science - July 25, 2022 Category: Science Authors: Linda Geddes Science correspondent Tags: Children's health Hepatitis B Hepatitis C Society Medical research Science Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche achieves good results in the first six months of 2022
Basel, 21 July 2022Group sales up 5%1 at constant exchange rates (CER) and 5% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for new medicines to treat severe diseases; as expected, the impact of biosimilars slows down furtherDiagnostics Divisionsales grow 11%; ongoing strong base business; demand for COVID-19 tests is expected to decline in the second half of the yearIFRSnet income increases by 12% (12% in Swiss francs), whilecore earnings per share are up 11%Highlights in the second quarter:EU approvals ofPolivy (first-line treatment for aggressive form of blood cancer),Lunsumio (follic...
Source: Roche Media News - July 21, 2022 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche achieves good results in the first six months of 2022
Group sales up 5%1 at constant exchange rates (CER) and 5% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for new medicines to treat severe diseases; as expected, the impact of biosimilars slows down furtherDiagnostics Divisionsales grow 11%; ongoing strong base business; demand for COVID-19 tests is expected to decline in the second half of the yearIFRSnet income increases by 12% (12% in Swiss francs), whilecore earnings per share are up 11%Highlights in the second quarter:EU approvals ofPolivy (first-line treatment for aggressive form of blood cancer),Lunsumio (follicular lymphoma) andT...
Source: Roche Investor Update - July 21, 2022 Category: Pharmaceuticals Source Type: news

Roche Launches Dual Antigen and Antibody Diagnostic Test for Hepatitis C Roche Launches Dual Antigen and Antibody Diagnostic Test for Hepatitis C
Roche has launched a new dual antigen and antibody diagnostic test for hepatitis C, the Swiss pharmaceuticals company said on Monday, which it says will give an earlier diagnosis of the virus.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - July 20, 2022 Category: Pathology Tags: Infectious Diseases News Source Type: news

Roche launches innovative dual antigen and antibody diagnostic test supporting the fight to eliminate the hepatitis C virus
Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.TheElecsys HCVDuo immunoassay enables significantly earlier diagnosis of active HCV infection, making it possible to get patients appropriate care sooner to stop both the disease progression and transmission.Basel, 18 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Elecsys ® HCV Duo immunoassay in countries that accept the CE Mark. Elecsys HCV Duo is the first available immunoassay that allows the simultaneous ...
Source: Roche Investor Update - July 18, 2022 Category: Pharmaceuticals Source Type: news

Roche launches innovative dual antigen and antibody diagnostic test supporting the fight to eliminate the hepatitis C virus
Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.TheElecsys HCVDuo immunoassay enables significantly earlier diagnosis of active HCV infection, making it possible to get patients appropriate care sooner to stop both the disease progression and transmission.Basel, 18 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Elecsys ® HCV Duo immunoassay in countries that accept the CE Mark. Elecsys HCV Duo is the first available immunoassay that allows the simultaneous ...
Source: Roche Media News - July 18, 2022 Category: Pharmaceuticals Source Type: news

FREE CONTACT HOUR: JHSON Virtual Nursing Grand Rounds
p{ margin:10px 0; padding:0; } table{ border-collapse:collapse; } h1,h2,h3,h4,h5,h6{ display:block; margin:0; padding:0; } img,a img{ border:0; height:auto; outline:none; text-decoration:none; } body,#bodyTable,#bodyCell{ height:100%; margin:0; padding:0; width:100%; } .mcnPreviewText{ display:none !important; } #outlook a{ padding:0; } img{ -ms-interpolation-mode:bicubic; } table{ mso-table-lspace:0pt; mso-table-rspace:0pt; } .ReadMsgBody{ width:100%; } .ExternalClass{ width:100%; } p,a,li,td,blockquote{ ...
Source: Johns Hopkins University and Health Systems Archive - July 13, 2022 Category: Nursing Source Type: news

Treatment for Hep C Up Among People Who Inject Drugs
TUESDAY, July 12, 2022 -- Among persons who inject drugs (PWID) with chronic hepatitis C virus (HCV) infection, the proportion in whom HCV RNA was detected decreased from 100 to 48 percent from 2006 to 2019, according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 12, 2022 Category: Pharmaceuticals Source Type: news

Better Outcomes Tied to More HCV Treatment for People Who Inject Drugs
(MedPage Today) -- A greater uptake in hepatitis C virus (HCV) treatment for people who inject drugs (PWID) at a community center led to decreases in liver disease and mortality, a longitudinal cohort study found. Among 1,323 PWID with chronic... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - July 12, 2022 Category: Gastroenterology Source Type: news

High Residual Liver Cancer Risk in HCV-Cured Cirrhosis High Residual Liver Cancer Risk in HCV-Cured Cirrhosis
Patients with cirrhosis cured of hepatitis C have a 410 times greater risk of hepatocellular carcinoma than the general population and need regular screening, researchers say.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 11, 2022 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Guidelines For Children and Postnatal Infectious Disease Testing
FRIDAY, July 1, 2022 -- Children aged<12 years who received postnatal infectious disease testing are exempt from repeat HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) testing prior to transplant surgery, according to research... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 1, 2022 Category: Pharmaceuticals Source Type: news